Dr. Anjlee Agarwal, is a National Award recipient and a pioneer in universal accessibility and sustainable mobility. In conversation with The Navhind Times, ...
Andy, who has retinal dystrophy, initially had avoidance anxiety and "wouldn't cross a road, wouldn't take the kids to school ...
Muscular Dystrophy Association Marks Rare Disease Day by Spotlighting Community Stories Driving Progress in Research, Care, and Advocacy ...
Sarepta Therapeutics (NASDAQ:SRPT) reported three-year top-line results from its EMBARK Phase 3 pivotal trial evaluating ...
In our biomarker-defined subpopulation, we observed a 0.27 effect size on the EMACC cognitive scale after only 6 months (2). For directional context, this magnitude compares favorably to the 18-month ...
PIP payments are currently worth between £29.20 and £187.45 each week, some £116.80 or £749.80 every four-week pay period.
Discusses 3-Year Topline Results From EMBARK Phase 3 Trial of ELEVIDYS in Duchenne Muscular Dystrophy January 26, ...
Dyne Therapeutics leverages its FORCE platform to target genetically driven muscle diseases. Read why I am bullish about DYN ...
The Nebraska Department of Health and Human Services will no longer seek to cap weekly paid hours for live-in family ...
In his CEO Commentary, Frederic Revah, Ph.D., underscores the dedication, expertise and successes of Genethon's 240 scientists and professional staff as they pursue new gene therapy treatments for ...
Sarepta Therapeutics SRPT announced positive three-year top-line data from Part 1 of the phase III EMBARK study, evaluating ...
INmune Bio, Inc. (NASDAQ: INMB), a clinical-stage inflammation and immunology company, presents the following letter to investors from David Moss, CEO: ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results